Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies

NCT03323398 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT03323398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03323398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
August 15, 2017
Completion date
August 18, 2021
Enrollment
79 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, relapsed/refractory solid tumor malignancies or lymphoma